Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8001 to 8050 of 8140 results

  1. Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction

    Awaiting development [GID-IPG10353] Expected publication date: 14 November 2024

    Interventional procedures guidance
    Awaiting development

  2. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]

    In development [GID-TA11450] Expected publication date: 16 October 2024

    Technology appraisal guidance
    In development

  3. Tenecteplase for treating acute ischaemic stroke [ID6306]

    In development [GID-TA11364] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Quality Standards Interim Process Guide: methods / process manual consultation

    We are listening to your views on this NICE process and methods. Comments close 15 May 2024.

    In consultation

  5. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    In development [GID-TA11318] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]

    In development [GID-TA10917] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  8. Fertility problems: assessment and treatment

    In development [GID-NG10263] Expected publication date: 29 May 2025

    NICE guideline
    In development

  9. Palopegteriparatide for treating chronic hypoparathyroidism ID6380

    In development [GID-TA11454] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  11. Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

    Awaiting development [GID-TA10752] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343

    In development [GID-TA11379] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 23 May 2024.

    Technology appraisal guidance
    In consultation

  14. Suspected sepsis: recognition, diagnosis and early management

    In development [GID-NG10412] Expected publication date: 13 August 2025

    NICE guideline
    In development

  15. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  16. Depression

    All NICE products on depression. Includes any guidance and quality standards.

    Topic page

  17. Olorofim for treating invasive fungal infections in people 16 years and over TS ID 11983

      Status ...

    Technology appraisal guidance
    Topic selection

  18. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436

    Awaiting development [GID-TA11532] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development [GID-TA11096] Expected publication date: 07 August 2024

    Technology appraisal guidance
    In development

  20. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development [GID-TA10994] Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Voxelotor for treating sickle cell disease [ID1403]

    In development [GID-TA10505] Expected publication date: 12 June 2024

    Technology appraisal guidance
    In development

  22. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: 25 September 2024

    Technology appraisal guidance
    In development

  23. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

    In development [GID-TA10653] Expected publication date: 22 May 2024

    Technology appraisal guidance
    In development

  24. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome [ID3947]

    In development [GID-TA10834] Expected publication date: 22 May 2024

    Technology appraisal guidance
    In development

  25. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued [GID-TA11124]

    Technology appraisal guidance
    Discontinued

  26. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  27. Obesity: clinical assessment and management (QS update)

    In development [GID-QS10183] Expected publication date: TBC

    Quality standard
    In development

  28. Obesity: prevention and lifestyle management (QS update)

    In development [GID-QS10184] Expected publication date: TBC

    Quality standard
    In development

  29. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  30. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  31. Adrenal insufficiency: identification and management

    In development [GID-NG10237] Expected publication date: 28 August 2024

    NICE guideline
    In development

  32. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    Awaiting development [GID-IPG10392] Expected publication date: 05 February 2025

    Interventional procedures guidance
    Awaiting development

  33. Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]

    In development [GID-HST10055] Expected publication date: 29 January 2025

    Highly specialised technologies guidance
    In development

  34. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    In development [GID-TA11255] Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathway

    In development [GID-HTE10047] Expected publication date: TBC

    Health technology evaluations
    In development

  36. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146

    Awaiting development [GID-TA11222] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  37. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development [GID-TA11161] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  38. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6428

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221

    In development [GID-TA11183] Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: TBC

    Technology appraisal guidance
    In development

  41. Unilateral MRI-guided focused ultrasound thalamotomy for moderate-to-severe tremor in Parkinson's disease

    Awaiting development [GID-IPG10375] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  42. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over ID6323

    In development [GID-TA11373] Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. MRI guided focused ultrasound subthalamotomy in parkinson's disease

    Awaiting development [GID-IPG10402] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  44. Guselkumab for treating moderately to severely active ulcerative colitis ID6237

    In development [GID-TA11247] Expected publication date: TBC

    Technology appraisal guidance
    In development

  45. Menopause: diagnosis and management

    In development [GID-NG10241] Expected publication date: TBC

    NICE guideline
    In development

  46. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development [GID-NG10216] Expected publication date: TBC

    NICE guideline
    In development

  47. Electrically stimulated intravesical therapy for Interstitial Cystitis

    Awaiting development [GID-IPG10362] Expected publication date: 29 January 2025

    Interventional procedures guidance
    Awaiting development

  48. Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

    In development [GID-TA11245] Expected publication date: TBC

    Technology appraisal guidance
    In development

  49. Transperineal laser ablation (TPLA) for treating lower urinary tract symptoms of benign prostatic hyperplasia using a ultra-micro invasive approach.

    Awaiting development [GID-IPG10268] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  50. Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]

    In development [GID-TA10962] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development